Relypsa, Inc. has announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company’s lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels. The open-label study of heart failure patients with chronic kidney disease is intended to explore dosing of RLY5016.

Read the full story here